Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (212${count})

  • Therapeutic Pipeline Program, 2018
    Development of ALK4290 as a Novel Parkinson's Therapeutic

    Study Rationale:
    There is clear evidence that the immune system plays an important role in the development and progression of Parkinson's disease. Novel therapies targeting the recruitment of immune...

  • 2022: Accelerated Therapeutics Program, 2024
    (SUPPLEMENT) Innovative Therapies for Parkinson’s Disease Through a Novel, Unexploited Gene Expression Mechanism Rooted in Human Genetics Enabling a Precision-medicine Approach

    Study Rationale: Parkinson’s disease (PD) and Alzheimer’s disease (AD) are neurodegenerative disorders caused by an accumulation of protein aggregates that leads to cell death. Genetic studies suggest...

  • Clinical Intervention Awards, 2012
    A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals with Parkinson’s Disease
    Objective/Rationale: In the twenty-first century the motor symptoms of Parkinson’s disease (PD) are typically well-managed. The neurocognitive symptoms of Parkinson’s disease often result in...
  • Rapid Response Innovation Awards, 2014
    Reduced Habitual Intrusions: An Early Marker of Parkinson's Disease?

    Study Rationale:                   
    Parkinson's disease is characterized by the loss of a neurotransmitter called dopamine in a part of the brain called the basal ganglia. Parts of this region are...

  • Fall 2020 RFA: Therapeutic Pipeline Program-Pre-Clinical, 2022
    Targeting Colony-stimulating Factor 1 Receptor (CSF1R) to Modify Disease Progression in Preclinical Experimental Models of Parkinson’s Disease

    Study Rationale: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by pronounced neuroimmune dysfunction. Although the disease is very common, no therapy is available...

  • Prescott Family Initiative at the Arizona Parkinson's Diseas, 2009
    Arizona Parkinson's Disease Consortium: Predictors of Parkinson’s Disease and Parkinson’s Disease-Dementia

    Promising Outcomes of Original Grant: 
    The goals of the original grant were to expand the number of PD patients enrolled, incorporate new questionnaires for recording non-motor manifestations of PD...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.